AAV vector and use thereof

By designing an AAV vector encoding a tat-degrading peptide, the problem of rapid degradation of traditional peptide drugs in the body and inability to cross the blood-brain barrier is solved, long-term intervention and wide delivery of central diseases have been achieved, and treatment effect and compliance have been significantly improved.

WO2024229777A1PCT designated stage expired Publication Date: 2024-11-14PRODEGRE THERAPEUTICS (SHANGHAI) CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/093379
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-11
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Traditional peptide drugs rapidly degrade in the body, resulting in short maintenance of effective drug concentrations, making it difficult to achieve long-term therapeutic effects, and cannot effectively cross the blood-brain barrier, making it difficult to treat central system diseases.

Method used

A AAV vector is designed to encode nucleic acid fragments of tat-degraded peptides that can be continuously expressed in the peripheral area and cross the blood-brain barrier and cell membranes, achieving long-term intervention in central diseases.

Benefits of technology

Through the use of AAV vectors, the wide and long-term delivery of degraded peptide drugs has been achieved, which significantly improves the effectiveness of chronic disease treatment and patient compliance, and solves the problem that traditional drugs are difficult to maintain effective concentrations and cross the blood-brain barrier.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023093379_14112024_PF_FP_ABST
    Figure CN2023093379_14112024_PF_FP_ABST
Patent Text Reader

Abstract

An AAV vector and a use thereof. The AAV vector comprises a nucleic acid fragment encoding a TAT-degradation peptide. The designed AAV vector comprising a nucleic acid fragment encoding a secretory TAT-degradation peptide can be continuously expressed on the periphery, the expressed degradation peptide crossing a blood-brain barrier and a cell membrane to realize long-acting intervention of central nervous diseases, or can be continuously expressed in the central nervous system to cross the cell membrane so as to exert an effect in both AAV infected cells and non-infected cells. That is, the AAV vector achieves the wide and long-acting delivery of a degradation peptide drug.
Need to check novelty before this filing date? Find Prior Art

Description

AAV vector and its application Technical Field

[0001] The present invention relates to an AAV vector and application thereof, and belongs to the field of adeno-associated virus vector drugs. Background Art

[0002] Traditional peptide drugs, especially those composed of pure natural amino acids, are often prone to rapid degradation in the body, resulting in a short maintenance time of effective drug concentration in the body, making it difficult to manifest the therapeutic effect of the drug. In addition, traditional peptide drugs cannot be taken orally and require repeated intramuscular injections. In addition, traditional peptide drugs are usually unable to efficiently cross the blood-brain barrier and have difficulty reaching the central nervous system to exert a therapeutic effect. Traditional degradable peptides are mostly used clinically for acute treatment (such as stroke), and have problems such as difficulty in maintaining effective drug concentrations in the body, low efficacy in treating chronic diseases, and poor compliance among patients with long-term injections.

[0003] In the face of the problems of peptide drugs composed of pure natural amino acids, such as easy rapid degradation in the body, short maintenance time of effective drug concentration in the body, difficulty in stably manifesting drug efficacy, and high individual heterogeneity, adeno-associated virus (AAV) treatment technology can be selected clinically. The core of this technology is an AAV vector drug that simply carries the target gene, the purpose of which is to express the target gene in the infected cells to supplement the missing / reduced protein of the infected cells. A one-time administration of AAV vector drugs can last for up to 5-10 years. However, this technology has significant disadvantages: ① The infection efficiency is low, and the intervention effect is limited to a small number of infected cells. ② Traditional adeno-associated viruses (AAV) or the proteins they encode cannot cross the blood-brain barrier and cell membranes, and it is difficult to achieve widespread intervention across infected cells, brain regions, and even peripheral centers.

[0004] Summary of the Invention

[0005] To solve the problems existing in the existing technology, we propose an AAV vector and its application.

[0006] The present invention first provides an AAV vector, which includes a nucleic acid segment encoding a tat-degrading peptide.

[0007] The degradation peptides described in the present invention refer to peptides that can target endogenous proteins and degrade them.

[0008] The tat-degrading peptide described in the present invention is a secretory tat-degrading peptide. The AAV vector designed by the present invention, which includes a nucleic acid fragment encoding the secretory tat-degrading peptide, can be continuously expressed in the periphery. The expressed degradation peptide can cross the blood-brain barrier and cell membranes to achieve long-term intervention in central nervous system diseases, or it can be continuously expressed in the central nervous system and cross cell membranes to exert its effects in both AAV-infected and non-infected cells. In other words, the AAV vector of the present invention achieves widespread and long-term delivery of degradation peptide drugs.

[0009] The tat mentioned in the present invention refers to the human immunodeficiency virus-1 transcription activator (HIV-1tat), which is a cell-penetrating peptide that enters cells in a non-toxic and efficient manner.

[0010] According to a specific embodiment of the present invention, preferably, the degradation peptide is: a peptide carrying a deg tag or a CTM tag that mediates degradation of endogenous proteins;

[0011] Preferably, the amino acid sequence of the deg tag is shown in SEQ ID NO.1;

[0012] SEQ ID NO. 1: RRRG;

[0013] Preferably, the amino acid sequence of the CTM tag is shown as SEQ ID NO.2;

[0014] SEQ ID NO. 2: KFERQ.

[0015] According to a specific embodiment of the present invention, preferably, the amino acid sequence of tat is as shown in SEQ ID NO.3;

[0016] SEQ ID NO. 3: YGRKKRRQRRR;

[0017] Preferably, the nucleic acid sequence encoding tat is shown as SEQ ID NO.4;

[0018] SEQ ID NO. 2: TATGGCAGGAAGAAGCGGAGACAGCGACGAAGA.

[0019] According to a specific embodiment of the present invention, preferably, the degradation peptide is βSyn-deg;

[0020] Wherein, the amino acid sequence of βsyn-deg is shown in SEQ ID NO.5;

[0021] SEQ ID NO.5: YGRKKRRQRRRRTKSGVYLVGRRRG;

[0022] Preferably, the nucleic acid sequence encoding βsyn-deg is shown as SEQ ID NO.6;

[0023] SEQ ID NO.6:

[0024] The DEG of the present invention, also known as degron, mediates the binding of α-synuclein (α-syn) to the proteasome in the tat-βsyn-degron structure, inducing α-synuclein degradation. The tat-βsyn-degron of the present invention can effectively and specifically reduce α-synuclein.

[0025] Physiological synuclein includes three types: α-synuclein (α-syn), β-synuclein (β-syn), and γ-synuclein (γ-syn). Physiological α-synuclein is a disordered monomer, while pathological synuclein is a monomer in a pathologically aggregated state, i.e., toxic α-synuclein. The secreted tat-degrading peptide described in the present invention can recognize and bind to α-synuclein through the encoded βsyn sequence, mediating targeted degradation.

[0026] According to a specific embodiment of the present invention, preferably, the degradation peptide is βsyn-CTM;

[0027] The amino acid sequence of βsyn-CTM is shown in SEQ ID NO. 7;

[0028] SEQ ID NO.7: YGRKKRRQRRRRTKSGVYLVGKFERQ.

[0029] According to a specific embodiment of the present invention, preferably, the AAV vector further comprises a promoter sequence;

[0030] Preferably, the promoter is a CMV promoter or a cell type-specific promoter;

[0031] Preferably, the cell type-specific promoter is EF1a or hSyn.

[0032] According to a specific embodiment of the present invention, preferably, the serotype of the AAV vector is: AAV9, AAV2, AAV5 or AAV8. The present invention does not explicitly limit the serotype of the AAV virus used. In actual application, the corresponding serotype AAV virus can be used according to different injection sites. For example, the serotype AAV9 with the ability to cross the blood-brain barrier can be selected for peripheral injection, and the serotype AAV2, AAV5 or AAV8 that do not have the ability to cross the blood-brain barrier can be selected for central local injection.

[0033] The second aspect of the present invention provides the use of the AAV vector in the preparation of a drug for intervening in central nervous system diseases. The drug has a broad and long-lasting effect on the intervention of central nervous system diseases.

[0034] The third aspect of the present invention provides a medicine comprising the AAV vector and pharmaceutically acceptable excipients.

[0035] According to a specific embodiment of the present invention, preferably, the drug is an injection; more preferably, the drug is a brain injection.

[0036] Beneficial effects of the present invention:

[0037] 1. The AAV vector designed by the present invention, which includes a nucleic acid fragment encoding a tat-degrading peptide, is superior to traditional nucleic acid interventions with low infection efficiency and intervention effects limited to a small number of infected cells. The AAV vector can continuously secrete degradation peptides through infected cells and then cross the blood-brain barrier and cell membrane to achieve extensive delivery and long-term intervention. In practical applications, the AAV vector of the present invention effectively solves the problems of traditional degradation peptide drugs being difficult to maintain effective drug concentrations in the body, low chronic disease treatment effects, and poor patient compliance with long-term injections. That is, the AAV vector of the present invention achieves extensive and long-term delivery of traditional degradation peptide drugs, improving their application scenarios.

[0038] 2. The AAV vector designed by the present invention, containing a nucleic acid fragment encoding a tat-degrading peptide, can be injected at a specific location during brain surgery, achieving sustained expression and thereby intervening across cell membranes and brain regions to intervene in disease. In other words, the AAV vector of the present invention enables injection into a single brain region and exerts its effects in multiple brain regions.

[0039] 3. The AAV vector designed in this invention, containing a nucleic acid fragment encoding a tat-degrading peptide, enables long-term expression of the target gene in the host, achieving the goal of long-term central nervous system intervention with a single dose. This addresses the problem that traditional AAV vectors act only on transfected cells, making them ineffective in treating central nervous system diseases, as well as the problem that traditional natural peptide drugs are rapidly degraded in the body, making it difficult to maintain effective drug concentrations in the body, resulting in poor efficacy.

[0040] 4. The AAV vector designed in the present invention is an improvement over traditional AAV vectors and traditional degradation peptide treatment methods. It also has the advantages of traditional AAV viral vector treatment methods, such as good safety, therapeutic potential, long-term efficacy and clinical feasibility, and the characteristic that polypeptide drugs can be genetically encoded. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] FIG1 is a schematic diagram of the vector structure after the tat-βsyn-degron nucleic acid fragment is inserted into the vector according to this embodiment.

[0042] FIG2 is a schematic diagram showing the expression of the AAV vector constructed in Example 1 in an animal model.

[0043] FIG3 shows the location and coordinates of the intracerebral injection in Experimental Example 1. The right panel of FIG3 shows the expression distribution of green fluorescent protein and tat.

[0044] FIG4 shows the levels of α-synuclein in the right substantia nigra and striatum of Parkinson's disease mouse models 3 months after injection.

[0045] Figure 5 shows the rotarod movement time and movement distance of Parkinson's disease mice 3 months after injection.

[0046] FIG6 shows the time spent in the center zone of the open field by Parkinson's disease mice 3 months after injection. DETAILED DESCRIPTION

[0047] In order to have a clearer understanding of the technical features, objectives and beneficial effects of the present invention, the technical solution of the present invention is now described in detail below, but it should not be understood as limiting the scope of implementation of the present invention.

[0048] Example 1

[0049] This embodiment provides a method for constructing an AAV vector comprising a tat-βsyn-degron structure, comprising:

[0050] (1) A nucleic acid fragment encoding tat-βsyn-degron was synthesized in vitro. The sequence is: SEQ ID NO.8:

[0051] (2) Construct an expression vector.

[0052] AAV2 / 9 serotype that infects local tissues such as local brain regions is used; tat-βSyn-degron transcription and expression are driven by a CMV promoter to construct an AAV expression vector (or pAAV virus).

[0053] Figure 1 shows the vector structure after insertion of the tat-βsyn-degron nucleic acid fragment in this example. The vector structure is designated pAAV-CMV-tat-βSyn-Deg-ef1a-egfp-3×flag. This virus can be purchased from Shanghai Heyuan Biotechnology.

[0054] Experimental Example 1

[0055] This experimental example provides the transmembrane expression of the AAV vector constructed in Example 1 in an animal model.

[0056] The schematic diagram of the expression of the AAV vector constructed in Example 1 in the animal model is shown in Figure 2. In Figure 2, the left side shows that cells transfected with the whole brain after local intracerebral injection or intravenous injection (injection method is shown on the right side of Figure 2) can express and secrete the pharmacologically effective tat-βsyn-deg degradation peptide for a long time. This degradation peptide can be secreted out of the host cell under the mediation of the tat transmembrane sequence and enter the surrounding infected or uninfected cells to exert its pharmacological effect. Based on the characteristics of AAV long-term expression of the target gene, this system works for a long time. We call this technology an in vivo brain cell pharmaceutical factory.

[0057] As shown in Figure 3, in the mouse striatum, 1 μl of 2 × 10 12 Thirty days after injection of the aforementioned pAAV virus at 500 μg / ml, the animals were perfused, fixed, and stained for Tat. High-level expression of the fluorescent protein (EGFP) was detected in the striatum. Due to its transmembrane diffusion, Tat's distribution was significantly wider than that of host cells expressing only EGFP. The enlarged image on the right side of Figure 3 also shows the emergence and diffusion of red Tat-positive cells from the green modeling cells, demonstrating the feasibility of the in vivo cell-based pharmaceutical factory technology.

[0058] Experimental Example 2

[0059] This experimental example provides information on the effectiveness of the AAV vector constructed in Example 1 in an animal model.

[0060] Existing literature demonstrates that the tat-βSyn-deg drug can target and reduce α-synuclein levels. However, the efficacy of existing tat-βSyn-deg drugs decreases dramatically after a single injection, necessitating daily intravenous administration. These drugs only provide minimal improvement in movement disorders and are unable to provide long-term, significant improvement in both motor and non-motor impairments associated with central nervous system degenerative diseases.

[0061] This experimental example explores the expression and efficacy of the AAV vector constructed in Example 1 in an animal model from the following two aspects.

[0062] (1) AAV control virus encoding a tat-scrambled polypeptide of the same length (hereinafter referred to as control virus) was injected into the left substantia nigra of a 9-month-old Parkinson's disease mouse model (A53T mouse), and the aforementioned pAAV-CMV-tat-βSyn-deg-ef1a-egfp-3xflag was injected into the right substantia nigra to continuously produce a peptide with pharmacological effects through the in vivo cellular pharmaceutical factory.

[0063] The results, shown in Figure 4, show that three months after injection, the AAV vector of the present invention significantly reduced α-synuclein (a-syn) levels in the right substantia nigra and its downstream striatum in a Parkinson's disease mouse model (A53T mice) compared to the left control virus, using GAPDH as an internal reference. This demonstrates that drugs produced in the brain by the AAV vector of the present invention via cell factories can exert their efficacy.

[0064] (2) A53T mice of 3 months, 6 months and 9 months of age were selected. The left substantia nigra of the A53T mice of the 3-month-old (3M), 6-month-old (6M) and 9-month-old (9M) groups were injected with the control virus (ctl) and the right substantia nigra was injected with the aforementioned pAAV-CMV-tat-βSyn-deg-ef1a-egfp-3xflag virus (deg). Three months later, compared with the A53T mice of the same age in the control group injected with the control virus on the right substantia nigra, the motor level of the 6-month-old, 9-month-old and 12-month-old animals in the rotarod (5 times) was significantly improved, and the anxiety level in the open field (10 minutes in Figure 6) was significantly reduced. The details are as follows:

[0065] Figure 5 shows that compared with control mice, 3-month-old and 6-month-old A53T mice injected with the control virus in the left substantia nigra and the pAAV-CMV-tat-βSyn-deg-ef1a-egfp-3xflag virus in the right substantia nigra showed significant increases in rotarod time and distance traveled after 3 months. In the 9-month-old group, tat-βSyn-deg had no significant effect on improving movement disorders in 9-month-old A53T mice due to the late intervention, which precluded the death of dopamine neurons in the substantia nigra. This suggests that tat-βSyn-deg's ability to degrade toxic proteins makes it more suitable for improving movement disorders in early and intermediate stages of Parkinson's disease.

[0066] Figure 6 shows that compared with control mice, A53T mice aged 3 months (3M), 6 months (6M), and 9 months (9M) received injections of the control virus (ctl) in the left substantia nigra and the aforementioned pAAV-CMV-tat-βSyn-deg-ef1a-egfp-3xflag virus (deg) in the right substantia nigra. Three months later, the proportion of time spent in the center of the open field significantly increased. This indicates that the tat-βSyn-deg drug can significantly improve non-motor impairments in Parkinson's disease that are less dependent on dopaminergic neurons in the substantia nigra, making it suitable for the treatment of late-stage Parkinson's disease.

[0067] The above experimental results not only prove the feasibility of the technology provided by the present invention, but also confirm that the AAV vector drug of the present invention can significantly improve the movement disorders and non-motor disorders of Parkinson's disease model mice. The AAV vector drug of the present invention achieves the effect of long-term treatment with a single dose, and solves the problem that ordinary AAV vector drugs cannot break through transfected cells. It can break through transfected cells and exert a therapeutic effect in multiple brain regions throughout the brain. The AAV vector drug of the present invention also solves the problem that traditional natural polypeptide drugs are difficult to maintain effective drug concentrations for a long time due to rapid degradation in the body, resulting in poor effectiveness and thus insignificant improvement of movement disorders and non-motor disorders.

Claims

1. An AAV vector comprising a nucleic acid segment encoding a tat-degrading peptide.

2. The AAV vector according to claim 1, in, The degradation peptide is: a peptide carrying a deg tag or a CTM tag that mediates endogenous protein degradation; Preferably, the amino acid sequence of the deg tag is as shown in SEQ ID NO.1; SEQ ID NO.1: RRRG; Preferably, the amino acid sequence of the CTM tag is shown as SEQ ID NO.2; SEQ ID NO.2: KFERQ.

3. The AAV vector according to claim 1, in, The amino acid sequence of tat is shown in SEQ ID NO.3; SEQ ID NO.3: YGRKKRRQRRR; Preferably, the nucleic acid sequence encoding tat is shown as SEQ ID NO.4; SEQ ID NO. 2: TATGGCAGGAAGAAGCGGAGACAGCGACGAAGA.

4. The AAV vector according to claim 1, in, The degradation peptide is βSyn-deg; Wherein, the amino acid sequence of βsyn-deg is shown in SEQ ID NO.5; SEQ ID NO.5: YGRKKRRQRRRRTKSGVYLVGRRRG; Preferably, the nucleic acid sequence encoding βsyn-deg is shown as SEQ ID NO.6; SEQ ID NO.6: CGTACTAAATCTGGTGTTTATTTGGTTGGTCGACGACGAGGC.

5. The AAV vector according to claim 1, in, The degradation peptide is βsyn-CTM; Wherein, the amino acid sequence of βsyn-CTM is shown in SEQ ID NO.7; SEQ ID NO.7: YGRKKRRQRRRRTKSGVYLVGKFERQ.

6. The AAV vector according to claim 1, in, The AAV vector further comprises a promoter sequence; Preferably, the promoter is a CMV promoter or a cell type-specific promoter; Preferably, the cell type specific promoter is: EF1a or hSyn.

7. The AAV vector according to claim 1, in, The serotype of the AAV vector is: AAV9, AAV2, AAV5 or AAV8.

8. Use of the AAV vector according to any one of claims 1 to 7 in the preparation of a drug for broad and long-term intervention in central nervous system diseases.

9. A medicament comprising the AAV vector according to any one of claims 1 to 7, and a pharmaceutically acceptable excipient.

10. The drug according to claim 9, in, The medicine is an injection; Preferably, the drug is a brain injection.

Citation Information

Patent Citations

  • Peptide directed protein knockdown

    CN104797603A

  • Methods and compositions for delivery of viral vectors across the blood-brain barrier

    CN111727243A

  • Methods and compositions for delivery of agents across the blood-brain barrier

    CN112703198A

  • Compositions and methods for treating synucleinopathies

    CN116096737A

  • Gene therapy of neurodegenerative diseases using AAV vectors

    WO2019068854A1